Federal Register / Vol. 82, No. 183 / Friday, September 22, 2017 / Notices 44429 

information and copies of the U.S. 

patent applications listed below may be 

obtained by communicating with the 

indicated licensing contact at the 

Technology Transfer and Intellectual 

Property Office (TTIPO), 5601 Fishers 

Lane, Suite 6D, MSC 9804, Rockville, 

MD 20892, tel: 301–496–2644, fax: 240– 

627–3117. A signed Confidential 

Disclosure Agreement will be required 

to receive copies of unpublished patent 

applications. 

SUPPLEMENTARY INFORMATION: 

Technology descriptions follow. 

Research Material: A Potent, BroadlyNeutralizing, Anti-HIV Antibody 

(35O22) That Binds a Novel Epitope 

Description of Technology: Millions of 

people are infected with HIV–1 

worldwide. In the U.S., there are about 

30,000 new cases of HIV infection 

reported annually. Researchers at NIAID 

are actively investigating broadly 

neutralizing anti-HIV–1 antibodies 

which can be used as therapeutics or 

prophylactics for HIV infection. 

NIAID and Scripps researchers have 

discovered a potent anti-HIV antibody 

(35O22) that binds a novel HIV epitope. 

This antibody neutralizes at least 80% 

of HIV isolates tested so far. The unique 

binding of 35O22 makes it an attractive 

candidate to combine with other HIV 

antibodies or antivirals in treating or 

preventing HIV infection. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications: 

• HIV–1 therapeutics 

• HIV–1 prophylactics 

Competitive Advantages: 

• Unique epitope 

• Broad neutralization of HIV isolates 

Development Stage: Pre-Clinical. 

Inventors: Mark Connors, John 

Mascola, Peter Kwong, Tongqing Zhou, 

Jinghe Huang, Byong Ha Kang, all of 

NIAID, NIH; Andrew Ward, Scripps 

Research Institute. 

Publications: Huang, J et al., Broad 

and potent HIV–1 neutralization by a 

human antibody that binds the gp41– 

gp120 interface. Nature 515, 138–142. 

Intellectual Property: Not applicable. 

Licensing Contact: Chris Kornak, 240– 

627–3705, chris.kornak@nih.gov. 

Collaborative Research Opportunity: 

The Technology Transfer and 

Intellectual Property Office (TTIPO) is 

seeking parties interested in 

collaborative research to further develop 

35O22 in combination with other NIAID 

antibodies. For collaboration 

opportunities, please contact Chris 

Kornak, 240–627–3705, chris.kornak@

nih.gov. 

Dated: September 12, 2017. 

Suzanne Frisbie, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2017–20232 Filed 9–21–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel; Drug 

Repurposing for Alzheimer’s Disease. 

Date: October 17, 2017. 

Time: 10:30 a.m. to 12:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute on Aging, 

Gateway Building, Suite 2W200, 7201 

Wisconsin Avenue, Bethesda, MD 20814 

(Telephone Conference Call). 

Contact Person: Anita H. Undale, Ph.D., 

MD, Scientific Review Branch, National 

Institute on Aging, Gateway Building, Suite 

2W200, 7201 Wisconsin Avenue, Bethesda, 

MD 20892, 240–747–7825, anita.undale@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.866, Aging Research, 

National Institutes of Health, HHS) 

Dated: September 18, 2017. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–20230 Filed 9–21–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Eye Institute; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Eye Institute 

Special Emphasis Panel NEI; Institutional 

Training Grant Applications. 

Date: October 16, 2017. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Garden Inn Bethesda, 7301 

Waverly Street, Bethesda, MD 20814. 

Contact Person: Jeanette M. Hosseini, 

Ph.D., Scientific Review Officer, NEI/DEA/ 

SRB, National Institutes of Health, 5635 

Fishers Lane, Suite 1300, Bethesda, MD 

20892, 301–451–2020, jeanetteh@

mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.867, Vision Research, 

National Institutes of Health, HHS) 

Dated: September 18, 2017. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–20178 Filed 9–21–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material,